循環器ジャーナル69巻4号

2021年10月発行

特集 プレシジョン・メディシン時代における腫瘍循環器学の重要性 Ⅱ章　がん医療の進歩と腫瘍循環器学

分子標的薬とがん治療関連心血管疾患（CTRCD）

著者： 坂東泰子¹

所属機関： ¹名古屋大学大学院医学系研究科循環器内科学

ページ範囲：P.566 - P.569

Point
・がん治療全般は循環器疾患のリスク因子の一つとして認知される．
・治療前には一般的な心血管病リスク〔動脈硬化性心血管疾患（ASCVD）リスクと心不全（HF）リスク〕の評価と，使用予定の抗がん剤で引き起こされる特有の副作用を考慮する．

参考文献

1) Hochhaus A, Saglio G, Hughes TP, et al:Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase:5-year update of the randomized ENESTnd trial. Leukemia 30:1044-1054, 2016

2) Cortes JE, Saglio G, Kantarjian HM, et al:Final 5-Year Study Results of DASISION:The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 34:2333-2340, 2016

3) Douxfils J, Haguet H, Mullier F, et al:Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival:A Systematic Review and Meta-analysis. JAMA Oncol 2:625-632, 2016

4) Curigliano G, Lenihan D, Fradley M, et al;ESMO Guidelines Committee. Electronic address:[e-mail]:Management of cardiac disease in cancer patients throughout oncological treatment:ESMO consensus recommendations. Ann Oncol 31:171-190, 2020. doi:10.1016/j.annonc.2019.10.023. PMID:31959335.

5) 小室一成（監修），日本腫瘍循環器学会編集委員会（編）：腫瘍循環器診療ハンドブック．メジカルビュー社，2020

6) 日本心エコー図学会：抗がん剤治療関連心筋障害の診療における心エコー図検査の手引．2020

7) Lenihan DJ:Progression of heart failure from AHA/ACC stage A to stage B or even C:can we all agree we should try to prevent this from happening? J Am Coll Cardiol 60:2513-2514, 2012. doi:10.1016/j.jacc.2012.08.1005.Epub 2012 Nov 14. PMID:23158534.

8) Lenihan DJ, Cardinale D, Cipolla CM:The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis 53:88-93, 2010. doi:10.1016/j.pcad.2010.06.002. PMID:20728695.

9) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al;ESC Scientific Document Group:2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology（ESC）. Eur Heart J 37:2768-2801, 2016

10) Armenian SH, Lacchetti C, Barac A, et al:Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers:American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35:893-911, 2017

11) Okada M, Imagawa J, Tanaka H, et al;DADI Trial Group, Japan:Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment. Clin Lymphoma Myeloma Leuk 18:353-360, 2018